These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 38743312)

  • 1. Pharmacotherapies for the Treatment of Progressive Supranuclear Palsy: A Narrative Review.
    Dunning EE; Decourt B; Zawia NH; Shill HA; Sabbagh MN
    Neurol Ther; 2024 Aug; 13(4):975-1013. PubMed ID: 38743312
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigational therapeutics for the treatment of progressive supranuclear palsy.
    Coughlin DG; Litvan I
    Expert Opin Investig Drugs; 2022 Aug; 31(8):813-823. PubMed ID: 35695010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How can we manage progressive supranuclear palsy syndrome with pharmacotherapy?
    Lozupone M; Dibello V; Daniele A; Solfrizzi V; Resta E; Panza F
    Expert Opin Pharmacother; 2024 Apr; 25(5):571-584. PubMed ID: 38653731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distinct involvement of the cranial and spinal nerves in progressive supranuclear palsy.
    Tanaka H; Martinez-Valbuena I; Forrest SL; Couto B; Reyes NG; Morales-Rivero A; Lee S; Li J; Karakani AM; Tang-Wai DF; Tator C; Khadadadi M; Sadia N; Tartaglia MC; Lang AE; Kovacs GG
    Brain; 2024 Apr; 147(4):1399-1411. PubMed ID: 37972275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early Stage of Progressive Supranuclear Palsy: A Neuropathological Study of 324 Consecutive Autopsy Cases.
    Nogami A; Yamazaki M; Saito Y; Hatsuta H; Sakiyama Y; Takao M; Kimura K; Murayama S
    J Nippon Med Sch; 2015; 82(6):266-73. PubMed ID: 26823029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tau PET imaging in progressive supranuclear palsy: a systematic review and meta-analysis.
    Jin J; Su D; Zhang J; Li X; Feng T
    J Neurol; 2023 May; 270(5):2451-2467. PubMed ID: 36633672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The diagnosis of progressive supranuclear palsy: current opinions and challenges.
    Ali F; Josephs K
    Expert Rev Neurother; 2018 Jul; 18(7):603-616. PubMed ID: 29902389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cathepsin S increases tau oligomer formation through limited cleavage, but only IL-6, not cathespin S serum levels correlate with disease severity in the neurodegenerative tauopathy progressive supranuclear palsy.
    Nübling G; Schuberth M; Feldmer K; Giese A; Holdt LM; Teupser D; Lorenzl S
    Exp Brain Res; 2017 Aug; 235(8):2407-2412. PubMed ID: 28493068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetics of Progressive Supranuclear Palsy.
    Im SY; Kim YE; Kim YJ
    J Mov Disord; 2015 Sep; 8(3):122-9. PubMed ID: 26413239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tau imaging with [
    Ishiki A; Harada R; Okamura N; Tomita N; Rowe CC; Villemagne VL; Yanai K; Kudo Y; Arai H; Furumoto S; Tashiro M; Furukawa K
    Eur J Neurol; 2017 Jan; 24(1):130-136. PubMed ID: 27797445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progressive supranuclear palsy: Neuropathology, clinical presentation, diagnostic challenges, management, and emerging therapies.
    DeRosier F; Hibbs C; Alessi K; Padda I; Rodriguez J; Pradeep S; Parmar MS
    Dis Mon; 2024 Aug; 70(8):101753. PubMed ID: 38908985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Critical appraisal of the role of davunetide in the treatment of progressive supranuclear palsy.
    Gold M; Lorenzl S; Stewart AJ; Morimoto BH; Williams DR; Gozes I
    Neuropsychiatr Dis Treat; 2012; 8():85-93. PubMed ID: 22347799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A clinicopathological study of vascular progressive supranuclear palsy: a multi-infarct disorder presenting as progressive supranuclear palsy.
    Josephs KA; Ishizawa T; Tsuboi Y; Cookson N; Dickson DW
    Arch Neurol; 2002 Oct; 59(10):1597-601. PubMed ID: 12374498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tau immunotherapy in Alzheimer's disease and progressive supranuclear palsy.
    Karimi N; Bayram Çatak F; Arslan E; Saghazadeh A; Rezaei N
    Int Immunopharmacol; 2022 Dec; 113(Pt B):109445. PubMed ID: 36410182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Divergent CSF τ alterations in two common tauopathies: Alzheimer's disease and progressive supranuclear palsy.
    Wagshal D; Sankaranarayanan S; Guss V; Hall T; Berisha F; Lobach I; Karydas A; Voltarelli L; Scherling C; Heuer H; Tartaglia MC; Miller Z; Coppola G; Ahlijanian M; Soares H; Kramer JH; Rabinovici GD; Rosen HJ; Miller BL; Meredith J; Boxer AL
    J Neurol Neurosurg Psychiatry; 2015 Mar; 86(3):244-50. PubMed ID: 24899730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Case report of a patient with unclassified tauopathy with molecular and neuropathological features of both progressive supranuclear palsy and corticobasal degeneration.
    Koga S; Metrick MA; Golbe LI; Santambrogio A; Kim M; Soto-Beasley AI; Walton RL; Baker MC; De Castro CF; DeTure M; Russell D; Navia BA; Sandiego C; Ross OA; Vendruscolo M; Caughey B; Dickson DW
    Acta Neuropathol Commun; 2023 Jun; 11(1):88. PubMed ID: 37264457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The MAPT gene is differentially methylated in the progressive supranuclear palsy brain.
    Huin V; Deramecourt V; Caparros-Lefebvre D; Maurage CA; Duyckaerts C; Kovari E; Pasquier F; Buée-Scherrer V; Labreuche J; Behal H; Buée L; Dhaenens CM; Sablonnière B
    Mov Disord; 2016 Dec; 31(12):1883-1890. PubMed ID: 27709663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rho Kinase Inhibition as a Therapeutic for Progressive Supranuclear Palsy and Corticobasal Degeneration.
    Gentry EG; Henderson BW; Arrant AE; Gearing M; Feng Y; Riddle NC; Herskowitz JH
    J Neurosci; 2016 Jan; 36(4):1316-23. PubMed ID: 26818518
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Messerschmidt K; Barthel H; Brendel M; Scherlach C; Hoffmann KT; Rauchmann BS; Rullmann M; Marek K; Villemagne VL; Rumpf JJ; Saur D; Schroeter ML; Schildan A; Patt M; Beyer L; Song M; Palleis C; Katzdobler S; Fietzek UM; Respondek G; Scheifele M; Nitschmann A; Zach C; Barret O; Madonia J; Russell D; Stephens AW; Koglin N; Roeber S; Herms J; Bötzel K; Bartenstein P; Levin J; Seibyl JP; Höglinger G; Classen J; Sabri O;
    J Nucl Med; 2022 Nov; 63(11):1754-1760. PubMed ID: 35422444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics of progressive supranuclear palsy presenting with corticobasal syndrome: a cortical variant.
    Ling H; de Silva R; Massey LA; Courtney R; Hondhamuni G; Bajaj N; Lowe J; Holton JL; Lees A; Revesz T
    Neuropathol Appl Neurobiol; 2014 Feb; 40(2):149-63. PubMed ID: 23432126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.